Raloxifene activates G protein-coupled estrogen receptor 1/Akt signaling to protect dopamine neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice

Neurobiology of Aging

Volumn 35, Issue 10, 2014, Pages 2347-2356

  Bourque, Mélanie ^a,b   Morissette, Marc ^a   Di Paolo, Thérèse ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Akt; Dopamine; GPER; MPTP; Neuroprotection; Raloxifene; Striatum

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; ANDROSTANOLONE; BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE; DOPAMINE TRANSPORTER; ESTRADIOL; G PROTEIN COUPLED RECEPTOR 30; HOMOVANILLIC ACID; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN BCL 2; PROTEIN KINASE B; RALOXIFENE; TESTOSTERONE; VESICULAR MONOAMINE TRANSPORTER 2; G PROTEIN COUPLED RECEPTOR; GPR30 PROTEIN, MOUSE; NEUROPROTECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; ENZYME ACTIVATION; INTRACELLULAR SIGNALING; MALE; MOUSE; NERVE CELL LESION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PHARMACOLOGICAL STIMULATION; PRIORITY JOURNAL; SUBSTANTIA NIGRA; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; ANIMAL; C57BL MOUSE; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINERGIC NEURONS; ESTRADIOL; MALE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; PROTO-ONCOGENE PROTEINS C-AKT; RALOXIFENE; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84903816068     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.03.017     Document Type: Article

References (66)

1. Abdelhamid R., Luo J., Vandevrede L., Kundu I., Michalsen B., Litosh V.A., Schiefer I.T., Gherezghiher T., Yao P., Qin Z., Thatcher G.R. Benzothiophene selective estrogen receptor modulators provide neuroprotection by a novel GPR30-dependent mechanism. ACS Chem. Neurosci. 2011, 2:256-268.
2. Al-Sweidi S., Morissette M., Bourque M., Di Paolo T. Estrogen receptors and gonadal steroids in vulnerability and protection of dopamine neurons in a mouse model of Parkinson's disease. Neuropharmacology 2011, 61:583-591.
3. Allen J.A., Diemer T., Janus P., Hales K.H., Hales D.B. Bacterial endotoxin lipopolysaccharide and reactive oxygen species inhibit Leydig cell steroidogenesis via perturbation of mitochondria. Endocrine 2004, 25:265-275.
4. Almey A., Filardo E.J., Milner T.A., Brake W.G. Estrogen receptors are found in glia and at extranuclear neuronal sites in the dorsal striatum of female rats: evidence for cholinergic but not dopaminergic colocalization. Endocrinology 2012, 153:5373-5383.
5. Aron L., Klein R. Repairing the parkinsonian brain with neurotrophic factors. Trends Neurosci. 2011, 34:88-100.
6. Audet-Walsh E., Lepine J., Gregoire J., Plante M., Caron P., Tetu B., Ayotte P., Brisson J., Villeneuve L., Belanger A., Guillemette C. Profiling of endogenous estrogens, their precursors, and metabolites in endometrial cancer patients: association with risk and relationship to clinical characteristics. J.Clin. Endocrinol. Metab. 2011, 96:E330-E339.
7. Bains M., Cousins J.C., Roberts J.L. Neuroprotection by estrogen against MPP+-induced dopamine neuron death is mediated by ERalpha in primary cultures of mouse mesencephalon. Exp. Neurol. 2007, 204:767-776.
8. Baraka A.M., Korish A.A., Soliman G.A., Kamal H. The possible role of estrogen and selective estrogen receptor modulators in a rat model of Parkinson's disease. Life Sci. 2011, 88:879-885.
9. Baydyuk M., Nguyen M.T., Xu B. Chronic deprivation of TrkB signaling leads to selective late-onset nigrostriatal dopaminergic degeneration. Exp. Neurol. 2011, 228:118-125.
10. Biju K., Zhou Q., Li G., Imam S.Z., Roberts J.L., Morgan W.W., Clark R.A., Li S. Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease. Mol. Ther. 2010, 18:1536-1544.
11. Birzniece V., Sata A., Sutanto S., Ho K.K. Neuroendocrine regulation of growth hormone and androgen axes by selective estrogen receptor modulators in healthy men. J.Clin. Endocrinol. Metab. 2010, 95:5443-5448.
12. Birzniece V., Sutanto S., Ho K.K. Gender difference in the neuroendocrine regulation of growth hormone axis by selective estrogen receptor modulators. J.Clin. Endocrinol. Metab. 2012, 97:E521-E527.
13. Bourque M., Dluzen D.E., Di Paolo T. Signaling pathways mediating the neuroprotective effects of sex steroids and SERMs in Parkinson's disease. Front. Neuroendocrinol. 2012, 33:169-178.
14. Bourque M., Liu B., Dluzen D.E., Di Paolo T. Sex differences in methamphetamine toxicity in mice: effect on brain dopamine signaling pathways. Psychoneuroendocrinology 2011, 36:955-969.
15. Bourque M., Morissette M., Cote M., Soulet D., Di Paolo T. Implication of GPER1 in neuroprotection in a mouse model of Parkinson's disease. Neurobiol. Aging 2013, 34:887-901.
16. Brailoiu E., Dun S.L., Brailoiu G.C., Mizuo K., Sklar L.A., Oprea T.I., Prossnitz E.R., Dun N.J. Distribution and characterization of estrogen receptor G protein-coupled receptor 30 in the rat central nervous system. J.Endocrinol. 2007, 193:311-321.
17. Callier S., Morissette M., Grandbois M., Pelaprat D., Di Paolo T. Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice. Synapse 2001, 41:131-138.
18. Campos F.L., Cristovao A.C., Rocha S.M., Fonseca C.P., Baltazar G. GDNF contributes to oestrogen-mediated protection of midbrain dopaminergic neurones. J.Neuroendocrinol. 2012, 24:1386-1397.
19. Cheng H.C., Kim S.R., Oo T.F., Kareva T., Yarygina O., Rzhetskaya M., Wang C., During M., Talloczy Z., Tanaka K., Komatsu M., Kobayashi K., Okano H., Kholodilov N., Burke R.E. Akt suppresses retrograde degeneration of dopaminergic axons by inhibition of macroautophagy. J.Neurosci. 2011, 31:2125-2135.
20. Creutz L.M., Kritzer M.F. Mesostriatal and mesolimbic projections of midbrain neurons immunoreactive for estrogen receptor beta or androgen receptors in rats. J.Comp. Neurol. 2004, 476:348-362.
21. D'Astous M., Mendez P., Morissette M., Garcia-Segura L.M., Di Paolo T. Implication of the phosphatidylinositol-3 kinase/protein kinase B signaling pathway in the neuroprotective effect of estradiol in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. Mol. Pharmacol. 2006, 69:1492-1498.
22. D'Astous M., Morissette M., Di Paolo T. Effect of estrogen receptor agonists treatment in MPTP mice: evidence of neuroprotection by an ER alpha agonist. Neuropharmacology 2004, 47:1180-1188.
23. Dennis M.K., Burai R., Ramesh C., Petrie W.K., Alcon S.N., Nayak T.K., Bologa C.G., Leitao A., Brailoiu E., Deliu E., Dun N.J., Sklar L.A., Hathaway H.J., Arterburn J.B., Oprea T.I., Prossnitz E.R. Invivo effects of a GPR30 antagonist. Nat. Chem. Biol. 2009, 5:421-427.
24. Ding Y.X., Xia Y., Jiao X.Y., Duan L., Yu J., Wang X., Chen L.W. The TrkB-positive dopaminergic neurons are less sensitive to MPTP insult in the substantia nigra of adult C57/BL mice. Neurochem. Res. 2011, 36:1759-1766.
25. Dluzen D.E., McDermott J.L., Liu B. Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/B1 mice. Neurotoxicol. Teratol. 1996, 18:603-606.
26. Duschek E.J., Gooren L.J., Netelenbos C. Effects of raloxifene on gonadotrophins, sex hormones, bone turnover and lipids in healthy elderly men. Eur. J. Endocrinol. 2004, 150:539-546.
27. Dutertre M., Smith C.L. Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J.Pharmacol. Exp. Ther. 2000, 295:431-437.
28. Franklin K., Paxinos G. The Mouse Brain in Stereotaxic Coordinates 1997, Academic Press, San Diego.
29. Frim D.M., Uhler T.A., Galpern W.R., Beal M.F., Breakefield X.O., Isacson O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc. Natl. Acad. Sci. U.S.A 1994, 91:5104-5108.
30. Fumagalli F., Racagni G., Riva M.A. Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease. Pharmacogenomics J. 2006, 6:95-104.
31. Gingerich S., Kim G.L., Chalmers J.A., Koletar M.M., Wang X., Wang Y., Belsham D.D. Estrogen receptor alpha and G-protein coupled receptor 30 mediate the neuroprotective effects of 17beta-estradiol in novel murine hippocampal cell models. Neuroscience 2010, 170:54-66.
32. Goekoop R., Barkhof F., Duschek E.J., Netelenbos C., Knol D.L., Scheltens P., Rombouts S.A. Raloxifene treatment enhances brain activation during recognition of familiar items: a pharmacological fMRI study in healthy elderly males. Neuropsychopharmacology 2006, 31:1508-1518.
33. Goekoop R., Duschek E.J., Knol D.L., Barkhof F., Netelenbos C., Scheltens P., Rombouts S.A. Raloxifene exposure enhances brain activation during memory performance in healthy elderly males; its possible relevance to behavior. Neuroimage 2005, 25:63-75.
34. Grandbois M., Morissette M., Callier S., Di Paolo T. Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice. Neuroreport 2000, 11:343-346.
35. Greendale G.A., Huang M.H., Wight R.G., Seeman T., Luetters C., Avis N.E., Johnston J., Karlamangla A.S. Effects of the menopause transition and hormone use on cognitive performance in midlife women. Neurology 2009, 72:1850-1857.
36. Hetman M., Gozdz A. Role of extracellular signal regulated kinases 1 and 2 in neuronal survival. Eur. J. Biochem. 2004, 271:2050-2055.
37. Jacobsen D.E., Melis R.J., Verhaar H.J., Olde Rikkert M.G. Raloxifene and tibolone in elderly women: a randomized, double-blind, double-dummy, placebo-controlled trial. J.Am. Med. Dir. Assoc. 2012, 13:e1-e7.
38. Jacobsen D.E., Samson M.M., Emmelot-Vonk M.H., Verhaar H.J. Raloxifene improves verbal memory in late postmenopausal women: a randomized, double-blind, placebo-controlled trial. Menopause 2010, 17:309-314.
39. Kilbourn M., Frey K. Striatal concentrations of vesicular monoamine transporters are identical in MPTP-sensitive (C57BL/6) and -insensitive (CD-1) mouse strains. Eur. J. Pharmacol. 1996, 307:227-232.
40. Kim S.R., Chen X., Oo T.F., Kareva T., Yarygina O., Wang C., During M., Kholodilov N., Burke R.E. Dopaminergic pathway reconstruction by Akt/Rheb-induced axon regeneration. Ann. Neurol. 2011, 70:110-120.
41. Kramer E.R., Aron L., Ramakers G.M., Seitz S., Zhuang X., Beyer K., Smidt M.P., Klein R. Absence of Ret signaling in mice causes progressive and late degeneration of the nigrostriatal system. PLoS Biol. 2007, 5:e39.
42. Kuppers E., Krust A., Chambon P., Beyer C. Functional alterations of the nigrostriatal dopamine system in estrogen receptor-alpha knockout (ERKO) mice. Psychoneuroendocrinology 2008, 33:832-838.
43. Lebesgue D., Traub M., De Butte-Smith M., Chen C., Zukin R.S., Kelly M.J., Etgen A.M. Acute administration of non-classical estrogen receptor agonists attenuates ischemia-induced hippocampal neuron loss in middle-aged female rats. PLoS One 2010, 5:e8642.
44. Lee D.K., Bird C.E., Clark A.F. Invivo metabolism of 3H-testosterone in adult male rats: effects of estrogen administration. Steroids 1975, 26:137-147.
45. Lee S.Y., Gong E.Y., Hong C.Y., Kim K.H., Han J.S., Ryu J.C., Chae H.Z., Yun C.H., Lee K. ROS inhibit the expression of testicular steroidogenic enzyme genes via the suppression of Nur77 transactivation. Free Radic. Biol. Med. 2009, 47:1591-1600.
46. Levin E.R. Gprotein-coupled receptor 30: estrogen receptor or collaborator?. Endocrinology 2009, 150:1563-1565.
47. Liu B., Dluzen D.E. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease. Clin. Exp. Pharmacol. Physiol. 2007, 34:555-565.
48. Mitra S.W., Hoskin E., Yudkovitz J., Pear L., Wilkinson H.A., Hayashi S., Pfaff D.W., Ogawa S., Rohrer S.P., Schaeffer J.M., McEwen B.S., Alves S.E. Immunolocalization of estrogen receptor beta in the mouse brain: comparison with estrogen receptor alpha. Endocrinology 2003, 144:2055-2067.
49. Morissette M., Jourdain S., Al Sweidi S., Menniti F.S., Ramirez A.D., Di Paolo T. Role of estrogen receptors in neuroprotection by estradiol against MPTP toxicity. Neuropharmacology 2007, 52:1509-1520.
50. Neubauer B.L., Best K.L., Clemens J.A., Gates C.A., Goode R.L., Jones C.D., Laughlin M.E., Shaar C.J., Toomey R.E., Hoover D.M. Endocrine and antiprostatic effects of raloxifene (LY156758) in the male rat. Prostate 1993, 23:245-262.
51. Okun M.S., McDonald W.M., DeLong M.R. Refractory nonmotor symptoms in male patients with Parkinson disease due to testosterone deficiency: a common unrecognized comorbidity. Arch. Neurol. 2002, 59:807-811.
52. Otto C., Fuchs I., Kauselmann G., Kern H., Zevnik B., Andreasen P., Schwarz G., Altmann H., Klewer M., Schoor M., Vonk R., Fritzemeier K.H. GPR30 does not mediate estrogenic responses in reproductive organs in mice. Biol. Reprod. 2009, 80:34-41.
53. Otto C., Rohde-Schulz B., Schwarz G., Fuchs I., Klewer M., Brittain D., Langer G., Bader B., Prelle K., Nubbemeyer R., Fritzemeier K.H. Gprotein-coupled receptor 30 localizes to the endoplasmic reticulum and is not activated by estradiol. Endocrinology 2008, 149:4846-4856.
54. Parcellier A., Tintignac L.A., Zhuravleva E., Hemmings B.A. PKB and the mitochondria: AKTing on apoptosis. Cell Signal 2008, 20:21-30.
55. Prossnitz E.R., Barton M. The G-protein-coupled estrogen receptor GPER in health and disease. Nat. Rev. Endocrinol. 2011, 7:715-726.
56. Quesada A., Lee B.Y., Micevych P.E. PI3 kinase/Akt activation mediates estrogen and IGF-1 nigral DA neuronal neuroprotection against a unilateral rat model of Parkinson's disease. Dev. Neurobiol. 2008, 68:632-644.
57. Rago V., Romeo F., Giordano F., Maggiolini M., Carpino A. Identification of the estrogen receptor GPER in neoplastic and non-neoplastic human testes. Reprod. Biol. Endocrinol. 2011, 9:135.
58. Ries V., Henchcliffe C., Kareva T., Rzhetskaya M., Bland R., During M.J., Kholodilov N., Burke R.E. Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A 2006, 103:18757-18762.
59. Rodriguez-Navarro J.A., Solano R.M., Casarejos M.J., Gomez A., Perucho J., de Yebenes J.G., Mena M.A. Gender differences and estrogen effects in parkin null mice. J.Neurochem. 2008, 106:2143-2157.
60. Ruffoli R., Giambelluca M.A., Scavuzzo M.C., Pasquali L., Giannessi F., Fornai F. MPTP-induced Parkinsonism is associated with damage to Leydig cells and testosterone loss. Brain Res. 2008, 1229:218-223.
61. Sanchez M.G., Bourque M., Morissette M., Di Paolo T. Steroids-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci. Ther. 2010, 16:e43-e71.
62. Subramaniam S., Unsicker K. ERK and cell death: ERK1/2 in neuronal death. FEBS J. 2010, 277:22-29.
63. Taylor H.S., Manson J.E. Update in hormone therapy use in menopause. J.Clin. Endocrinol. Metab. 2011, 96:255-264.
64. Yaffe K., Krueger K., Cummings S.R., Blackwell T., Henderson V.W., Sarkar S., Ensrud K., Grady D. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am. J. Psychiatry 2005, 162:683-690.
65. Yang L.C., Zhang Q.G., Zhou C.F., Yang F., Zhang Y.D., Wang R.M., Brann D.W. Extranuclear estrogen receptors mediate the neuroprotective effects of estrogen in the rat hippocampus. PLoS One 2010, 5:e9851.
66. Zheng P. Neuroactive steroid regulation of neurotransmitter release in the CNS: action, mechanism and possible significance. Prog. Neurobiol. 2009, 89:134-152.